(IMTX) Immatics N.V. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IMTX) Immatics N.V. Complete Analysis Pack
Unlock Strategic Clarity
This Immatics N.V. BCG Matrix helps you understand how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs. It is used for strategy, portfolio review, and investment analysis, and this page already shows a real preview of the actual report content. Buy the full version to access the complete ready-to-use analysis.
Stars
IMA203 — Phase I lead ACTengine candidate
IMA203 is Immatics N.V. lead ACTengine candidate and its most advanced disclosed program. It is in Phase I for recurrent or treatment-resistant solid tumors, so it is the clearest near-term value driver in the pipeline. The Phase I readout will matter most for BCG "Stars" positioning.
IMA202 — Phase I MAGEA1 TCR-T
IMA202 is a Phase I MAGEA1 TCR-T in Immatics' core ACTengine portfolio, aimed at melanoma-associated antigen 1 across several solid tumors. It has clinical visibility, but still no commercial share or product revenue, so it fits "Stars" only on pipeline promise, not on sales. As of the latest 2025 reporting, its value is still driven by early human data, while Immatics had no IMA202 commercialization to date.
IMA201 — Phase I MAGEA4/8 TCR-T
IMA201 is Immatics N.V.’s Phase I TCR-T program against MAGEA4/MAGEA8, two melanoma-associated antigens found in solid tumors, so it broadens the same soluble-target platform family. In the BCG Matrix, it fits as a Star: early clinical stage, but tied to a high-value solid-tumor immunotherapy market and a key growth driver for the pipeline.
ACTengine™ — 3 Phase I assets
ACTengine™ is Immatics N.V.’s lead adoptive cell therapy platform, and its 3 Phase I assets: IMA201, IMA202, and IMA203, are the core clinical drivers of future upside. This is the company’s main shot at converting its T-cell receptor science into larger, later-stage value.
- 3 Phase I assets in one platform
- Lead adoptive cell therapy engine
- Main source of future pipeline upside
The portfolio is still early, so value depends on Phase I safety, activity, and dose data. In BCG terms, this is a "Star" only if clinical execution stays strong and funding supports the next steps.
Genmab collaboration — TCR bispecifics
Genmab gives Immatics a strategic leg in T-cell engaging bispecific immunotherapies, broadening it beyond ACTengine. The deal adds a second modality, which can spread pipeline risk and widen future market reach. That matters because Immatics is building from cell therapy into a more scalable engager platform.
- Second modality, not just ACTengine
- Boosts development reach and capacity
- Targets T-cell engagement in solid tumors
- Improves long-term market optionality
Immatics’ 3 Phase I Stars: IMA203 Leads the Near-Term Catalyst
Immatics N.V.’s "Stars" are its 3 ACTengine Phase I assets: IMA201, IMA202, and IMA203. In the latest 2025 reporting, all 3 still lacked product revenue, so their BCG value rests on early clinical data and future solid-tumor upside. IMA203 is the key near-term catalyst because it is the most advanced disclosed program.
| Asset | Stage | BCG signal |
|---|---|---|
| IMA201 | Phase I | Star |
| IMA202 | Phase I | Star |
| IMA203 | Phase I | Star |
What is included in the product
Detailed Word Document
Immatics N.V. BCG Matrix spots its pipeline across Stars, Question Marks, Cash Cows, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
Quick BCG view for Immatics N.V. to spot growth, cash, and drag areas fast.
Reference Sources
Provides a credible source trail for Immatics N.V., helping decision-makers verify key claims quickly and trust the analysis.
Cash Cows
GSK collaboration
GSK is Immatics N.V.'s main partnering engine for novel adoptive cell therapies, and the deal can bring non-dilutive cash plus milestone payments without a marketed product. The collaboration is worth up to about $1 billion in potential milestone and royalty value, so it is the closest thing to a cash-cow asset in the portfolio. It helps fund R&D while keeping equity dilution lower.
MD Anderson collaboration
Immatics N.V.’s MD Anderson collaboration is a clear Cash Cow because it supports multiple research and clinical programs, not just one asset. The deal adds scientific validation, access to top oncology expertise, and can bring partnered funding, which lowers R&D burn. That matters more than product sales here, since the value is strategic support and shared development risk.
Celgene collaboration
The Celgene collaboration is an external alliance that supports Immatics N.V.’s adoptive cell therapy work and helps share R&D costs with a partner. In BCG terms, it is cash-supportive, but it is not yet a mature franchise; it mainly reduces burn rather than driving large product revenue.
Genmab collaboration
Genmab collaboration widens Immatics N.V.’s bispecific immunotherapy pipeline and can add future milestone and licensing revenue, but it is not a product cash generator today. It mainly works as a financing and external validation lever, helping fund R&D while the program matures. In BCG terms, this is a cash-cow-like partner asset only if milestone receipts start to scale.
- Pipeline expansion, not product sales
- Possible milestone and licensing income
- Today: funding and validation value
Partnering model — non-dilutive funding
Immatics’ partnering model is its cash-cow support layer: collaboration economics, not product sales, help fund R&D. In 2024, it reported no approved drug but still used partner cash to keep the pipeline moving; this is non-dilutive funding that can reduce equity raises and stretch runway.
- Partner cash funds R&D
- No approved drug yet
- Supports lower dilution
Immatics’ Cash Engine Is Partnerships, Not Product Sales
Immatics N.V.'s Cash Cows are its partnerships, not drug sales. GSK is the key anchor, with up to about $1 billion in milestones and royalties, while MD Anderson, Celgene, and Genmab help fund R&D and cut burn. No approved product means the cash flow is still partner-led, not franchise-led.
| Asset | Cash role | Value |
|---|---|---|
| GSK | Top funding engine | Up to $1B |
| MD Anderson | Shared R&D support | Non-dilutive |
Full Version Awaits
Immatics N.V. Reference Sources
The Immatics N.V. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No sample pages, no watermarks, and no demo content—just the full, ready-to-use report. Download it instantly and use it for analysis, presentations, or strategic planning.
Dogs
No approved product
Immatics N.V. is a clinical-stage company, so it has 0 approved products and 0 marketed drugs to place in a true Dog bucket.
That makes the Dogs quadrant effectively empty on a product basis, because there is no commercial asset generating mature, low-growth cash flow.
Any value today sits in pipeline candidates, not in a legacy product with shrinking returns.
No recurring product sales
Immatics N.V. has no disclosed recurring product sales because it has no approved medicines on the market. So there is no low-growth, low-share revenue base here, and nothing is sitting as a declining cash trap. The Dogs label fits only in the sense of no sales yet, not weak legacy sales.
No legacy brand
Immatics N.V. has no legacy brand to classify as a Dog. In 2025, it remained a clinical-stage company built on discovery and early development, with no marketed product franchise to defend or turn around. That means there is no shrinking old asset draining management focus or cash; the main value is still in pipeline progress and trial data.
No mature low-share asset
Immatics N.V. shows no clear Dog asset: all named programs are still precommercial, so none are mature products with weak share in a stable market. The portfolio is built on clinical and preclinical value, not on declining legacy sales, so the usual Dog profile does not appear.
- All named assets remain precommercial
- No mature, weak-share product is shown
- Dog bucket is not a fit here
No disclosed divestiture target
Immatics N.V. shows no disclosed divestiture target in its pipeline, because it has no legacy commercial product to abandon. The company is still putting capital into science-led programs like ACTengine and TCR discovery, so the Dog bucket stays empty.
That fits a development-stage model: no meaningful product sales, no brand cleanup, and no obvious cash drain from old assets. The focus is on clinical milestones, not divestitures.
- No legacy product to sell
- R&D-led pipeline stays active
- Dog bucket remains largely empty
Immatics Has No Dog Assets: All Value Is Still in Clinical Progress
Immatics N.V. has no Dog asset in 2025/2026 because it still has 0 approved products and 0 marketed drugs. With no product sales, there is no low-growth, weak-share legacy brand to drain cash. The Dog bucket stays empty while value sits in clinical progress.
| Metric | 2025/2026 |
|---|---|
| Approved products | 0 |
| Marketed drugs | 0 |
| Product sales | 0 |
Question Marks
IMA204 — preclinical tumor-stroma program
IMA204 is a preclinical tumor-stroma program that targets tumor stroma cells, so it fits the Question Mark bucket: high upside, but no proven clinical position yet. Clinical probability is still unproven, and market share is effectively 0 because there are no human efficacy data or revenue today.
That makes it a high-risk, high-reward asset for Immatics N.V., with value driven by future translation from preclinical work into the clinic.
IMA401 — preclinical TCR bispecific
IMA401 is a preclinical TCR bispecific that targets cancer testis antigens in solid tumors, so it sits in the Question Mark box. It has no clinical data yet, which means proof of concept is still missing. The program likely needs heavy R&D spend before it can move toward Star status, with success still tied to early clinical conversion.
IMA402 — preclinical solid-tumor program
IMA402 is still a Question Mark in Immatics N.V. BCG Matrix because it is a preclinical bispecific solid-tumor program with no proven market share yet. In 2025, preclinical assets still carry high upside, but they also face long timelines, high failure risk, and heavy R&D spend before any clinical data can support value. For now, its value is strategic optionality, not cash flow.
IMA101 — exploratory cancer program
IMA101 is disclosed only as a cancer-treatment program, with no clinical stage given in the source data. That makes it a high-uncertainty growth option in Immatics N.V.'s BCG Matrix, closer to a question mark than a proven asset. In 2025, Immatics reported €0.0 million product revenue and continued to fund R&D from cash and collaborations.
Its value depends on whether early data can justify higher trial spend and later-stage development.
- Disclosed as cancer treatment
- No clinical stage provided
- High uncertainty, not proven
- R&D-funded growth option
IMA301 — allogeneic cellular therapy
IMA301 sits in the Question Mark box: it is an allogeneic cellular therapy candidate with early evidence only, and no later-stage proof yet. That means Immatics N.V. must fund more clinical work and show clear response and safety data before the asset can justify scale-up. In 2025, the company still depended on capital-intensive R&D to advance this kind of platform.
- Early-stage allogeneic asset
- No late-stage proof yet
- Needs capital and data
- Potential upside, but high risk
Immatics’ Pipeline: Promising, But Still Unproven
Immatics N.V. question marks are early-stage, high-upside assets with no proven market share yet. In 2025, the company reported €0.0 million product revenue, so these programs still depend on R&D spend and clinical conversion, not cash flow. IMA204, IMA401, IMA402, IMA101, and IMA301 remain value options, but each still lacks late-stage proof.
| Program | Status | 2025 view |
|---|---|---|
| IMA204 | Preclinical | Question Mark |
| IMA401 | Preclinical | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.